Loading clinical trials...
Loading clinical trials...
It is a single-arm, open-label clinical study to assess the safety and efficacy of the C752 CAR-T Cells for patients with CD19+ refractory/relapsed B cell non-Hodgkin lymphoma.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Collaborators
NCT07284433 · Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, and more
NCT07188558 · Large B-cell Lymphoma, Lymphoma, B-Cell, and more
NCT04328298 · Hematopathology Eligible or CAR-t Cell Treatment
NCT04161248 · Lymphoma, B-Cell
NCT06528301 · Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), and more
920th Hospital of Joint LogisticsSupport Force of People's Liberation
Kunming, Yunnan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions